viimane versioon :
18/07/2024
uurimisrühmad - Pharmaceutical Research and Development, Pfizer Inc   pdf  
Ameerika ühendriigid
farmaatsialaboratoorium
Pharmaceutical Research and Development, Pfizer Inc
Andover
Email
Viited   Viited   (2)  
1
Physicochemical stability of PF-05280014 (trastuzumab-qyyp; TrazimeraTM), a trastuzumab biosimilar, under extended in-use conditions.
Weiser S, Burns C, Zartler E (Sarah.Weiser@pfizer.com)
J Oncol Pharm Practice - 2023 - ;29,3:
2
Physicochemical stability of PF-06439535 (bevacizumab-bvzr; Zirabev®), a bevacizumab biosimilar, under extended in-use conditions.
Weiser S, Burns C, Zartler E. (Sarah.Weiser@pfizer.com)
J Oncol Pharm Practice - 2022 - ;29, 5: 1032-1043

ingredientide nimekiri   molekulid uuritud   (2)  
vähiravimite Süsteravim Bevacizumab
vähiravimite Süsteravim Trastuzumab

  Mentions Légales